Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...
Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...
6d
Zacks.com on MSNUltragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/YUltragenyx Pharmaceutical RARE reported fourth-quarter 2024 loss of $1.39 per share, wider than the Zacks Consensus Estimate ...
Who are the leading players in the Evkeeza market? Key players in the Evkeeza market include the notable Regeneron Pharmaceuticals Inc., contributing significantly to the market growth.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results